CO4790100A1 - Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis - Google Patents

Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis

Info

Publication number
CO4790100A1
CO4790100A1 CO98053593A CO98053593A CO4790100A1 CO 4790100 A1 CO4790100 A1 CO 4790100A1 CO 98053593 A CO98053593 A CO 98053593A CO 98053593 A CO98053593 A CO 98053593A CO 4790100 A1 CO4790100 A1 CO 4790100A1
Authority
CO
Colombia
Prior art keywords
composition
tween
statement
detergent
cancer
Prior art date
Application number
CO98053593A
Other languages
English (en)
Inventor
Nabil Hanna
Sary Braslawsky
Kandasany Harihara
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of CO4790100A1 publication Critical patent/CO4790100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición que comprenda:(a) Una ADMIXTURE (Mezcla añadida) comprendiendo un antigen cáncer, viral o parasítico expresado mediante dicho cáncer, viralmente o parasíticamente células infectadas y una formulación antigen microfluida, dicha formulación antigen comprende: (i) Un detergente estabilizante. (ii) Un agente mecelle formante, y(iii) Un aceite biodegradable y biocompatible. Dicha formulación antigen siendo formulada como una emulsión de aceite estable en agua, yb) por lo menos un agente el cual es capaz de neutralizar o sub regular la actividad de factores inmunosupresivos.La composición de la declaración 1 en la cual dicha formulación antigen consiste esencialmente de dicho detergente estabilizante, agente micelle - formante, y aceite biocompatible. La composición de la declaración 1 en la cual el detergente es seleccionado del grupo que consta de TWEEN 80, TWEEN 20, TWEEN 40, TWEEN 60, ZWITTERGENT 3 - 12 TEEPOL HB7 y SPA 85. La composición de declaración en la cual dicho detergente es proporcionado en una cantidad que varia aproximadamente de 0.05 a 05% La composición de la declaración 1 en la cual dicho agente de micelle forming tiene un balance hidrófilo lipofilo de entre 0 y 2
CO98053593A 1997-09-18 1998-09-17 Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis CO4790100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93335997A 1997-09-18 1997-09-18

Publications (1)

Publication Number Publication Date
CO4790100A1 true CO4790100A1 (es) 1999-05-31

Family

ID=25463798

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98053593A CO4790100A1 (es) 1997-09-18 1998-09-17 Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis

Country Status (19)

Country Link
US (4) US20010018054A1 (es)
EP (1) EP1015031A4 (es)
JP (1) JP2001516727A (es)
KR (1) KR100540267B1 (es)
CN (1) CN1234413C (es)
AR (1) AR013012A1 (es)
AU (1) AU742216B2 (es)
CA (1) CA2303178A1 (es)
CO (1) CO4790100A1 (es)
HK (1) HK1033653A1 (es)
IL (2) IL134937A0 (es)
IN (1) IN190792B (es)
MY (1) MY131805A (es)
NO (1) NO20001413L (es)
RU (1) RU2219947C2 (es)
SA (1) SA98190719B1 (es)
TW (1) TWI252108B (es)
WO (1) WO1999013912A1 (es)
ZA (1) ZA988461B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO2001064164A2 (en) * 2000-02-28 2001-09-07 Genesegues, Inc. Nanocapsule encapsulation system and method
US7244232B2 (en) * 2001-03-07 2007-07-17 Biomed Solutions, Llc Process for identifying cancerous and/or metastatic cells of a living organism
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
NZ552128A (en) 2004-08-03 2009-09-25 Transtech Pharma Inc Rage fusion proteins without Fc hinge region and methods of use
MX2007001556A (es) * 2004-08-03 2008-03-05 Transtech Pharma Inc Proteinas de fusion del receptor para los productos finales glucados avanzados y metodos de uso.
JP5314428B2 (ja) * 2005-12-23 2013-10-16 ジーコデール システムズ アクチボラゲット 測位用パターン
EP1989227A2 (en) * 2006-02-09 2008-11-12 Transtech Pharma, Inc. Rage fusion proteins and methods of use
CA2651348A1 (en) * 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2009055005A2 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CN102803292A (zh) 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
WO2011042548A1 (en) * 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2640359A4 (en) * 2010-11-18 2015-11-04 Gen Hospital Corp NEW COMPOSITIONS AND USES OF BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
EP3705498A1 (en) 2013-08-22 2020-09-09 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
WO2016036960A1 (en) 2014-09-03 2016-03-10 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
HRP20230706T1 (hr) 2017-05-04 2023-10-13 Acceleron Pharma Inc. Fuzijski proteini tgf-beta receptora tipa ii i njihove upotrebe
KR20200130709A (ko) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
CN114814223A (zh) * 2022-04-20 2022-07-29 昆明市妇幼保健院 一种用于监测及控制疟原虫治疗的系统及设备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052A (en) * 1845-05-13 Tktjss
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
MX9204376A (es) * 1991-07-25 1993-02-01 Idec Pharma Corp Composiciones y metodos para inducir respuestas citotoxicas de los linfocitos t.
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents

Also Published As

Publication number Publication date
HK1033653A1 (en) 2001-09-14
TWI252108B (en) 2006-04-01
EP1015031A4 (en) 2004-03-17
US6998125B2 (en) 2006-02-14
IL134937A (en) 2008-04-13
CN1234413C (zh) 2006-01-04
IN190792B (es) 2003-08-23
CA2303178A1 (en) 1999-03-25
KR20010024109A (ko) 2001-03-26
AU742216B2 (en) 2001-12-20
AU9565898A (en) 1999-04-05
ZA988461B (en) 1999-03-30
EP1015031A1 (en) 2000-07-05
IL134937A0 (en) 2001-05-20
RU2219947C2 (ru) 2003-12-27
US20010019715A1 (en) 2001-09-06
AR013012A1 (es) 2000-11-22
JP2001516727A (ja) 2001-10-02
US20060153848A1 (en) 2006-07-13
SA98190719B1 (ar) 2006-08-06
NO20001413L (no) 2000-05-18
CN1279616A (zh) 2001-01-10
US20040137014A1 (en) 2004-07-15
WO1999013912A1 (en) 1999-03-25
US20010018054A1 (en) 2001-08-30
KR100540267B1 (ko) 2006-01-10
NO20001413D0 (no) 2000-03-17
MY131805A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
CO4790100A1 (es) Composicion cinergetica y metodos para tratar crecimientos neoplasicos o cancerosos y para restaurar o estimular hema- topoiesis
AR002255A1 (es) Una composicion que comprende una formulacion de antigeno microfluidizada y usos de dicha formulacion.
ES2134360T3 (es) Formulaciones de perfume.
ES2180636T3 (es) Emulsiones antimicrobianas de aceite en agua.
ES2169759T3 (es) Procedimiento de preparacion de emulsiones y microcapsulas que contienen aceite natural y uso del mismo.
BR9007501A (pt) Emulsoes injetaveis multifasicas de tipo a/o/a,adjuvantes oleosos,e,processo para a preparacao e composicoes injetaveis
PA8541401A1 (es) Empleo de etoxilatos de alcoholes grasos como favorecedores de la penetracion
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
ES2181725T3 (es) Inhibidores de hiv proteasa.
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2093269T3 (es) Microemulsiones del tipo agua en aceite.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
CO5200793A1 (es) Microemulsion antimicrobiana para propositos multiples que contiene un agente tensoactivo cationico
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
NO874150L (no) Preparater inneholdende propylenglykol og/eller polyetylenglykol og urinstoff som aktive hovedkomponenter og anvendelse derav.
ES2196613T3 (es) Composiciones cosmeticas estables.
AR011435A1 (es) Emulsion de agua en aceite, su utilizacion, composicion cosmetica y/o dermatologica que la contiene, procedimiento de tratamiento cosmetico yutilizacion de la asociacion de polialquil polieter siloxano y de un polimero de tipo ester de acido graso de glicol polioxialquilenado
CO5070657A1 (es) Composiciones farmaceuticas para tratar infecciones virales y metodo para hacerlas
FR2718353A1 (fr) Compositions pharmaceutiques à base de produits biologiques atoxiques destinées à la protection locale des muqueuses génitales et rectales.
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
AR029081A1 (es) Una composicion de enjuague con agentes de beneficio para el cuidado del cabello y la piel en emulsion multiple' agua en aceite en agua '
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PA8459501A1 (es) Formulaciones parasiticidas